Automated Microbiology Market Overview
The Global Automated Microbiology Market was valued at US$ 6.73 Billion in 2025 and is expected to reach US$ 13.50 Billion in 2033, growing at a CAGR of 9.1% during the forecast period (2026–2033).
Automated microbiology is a cutting-edge technology for delivering more efficient, accurate, and timely test findings in microbiological research and development. Its quick results aid in detecting infections, including Ebola, chickenpox, smallpox, rubella, measles, mumps, influenza, and others. This technology automates crucial activities such as microbe separation, detection, categorization, and measurement in the biological, ecological, and food industries.
Automated Microbiology Market Summary and Scope
Metrics | Details |
Market CAGR | 9.1% |
Segments Covered | By Technology, By Type, By Cancer Type, and By Region |
Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
Fastest Growing Region | Asia Pacific |
Largest Market Share | North America |
Automated Microbiology Market Dynamics and Trends
A New Era in Clinical Microbiology with Automation and Molecular Diagnostics is expected to drive market growth.
Testing approaches based on organism growth on various liquid and solid media are being phased out in favor of newer methods that improve the pace of organism identification while also increasing sensitivity and specificity. Most of these new techniques are based on nucleic hybridization and polymerase-chain-reaction technology. They range from single-organism or organism family identification to multiplexed syndromic panels, which can simultaneously examine for the presence of multiple suspect organisms based on the patient's symptoms. Similarly, the clinical microbiology laboratory now has access to a level of automation previously only seen in the clinical laboratory's chemistry and hematology departments. Moreover, When appropriately implemented into the laboratory process, these transitions have been found to improve patient care. Collectively, the clinical microbiology laboratory is coming into a new era of technology and patient care that will bring about dramatic changes to conventional testing and organism identification. Thus, the market is expected to drive in the forecast period from the above statements.
Restraint:
High costs and large footprints of these systems, and a scarcity of qualified personnel to operate them are the factors the market is expected to hamper in the forecast period.
Automated Microbiology Market Segmentation Analysis
Clinical Laboratories segment is expected to hold the largest market share in automated microbiology market
The clinical microbiology laboratory saves time and enhances laboratory quality management by reducing its time to generate findings. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.
Automated Microbiology Companies and Competitive Landscape
Major key players in the automated microbiology market are Becton Dickinson and Company, Microbiology International, Thermo Fisher Scientific, Inc., bioMérieux, Inc., Cardinal Health, Beckman Coulter, Inc., Merck KGaA, Rapid Micro Biosystems, Inc., Clever Culture Systems and Zhuhai Meihua Medical Technology Ltd.
Thermo Fisher Scientific:
Overview:
Thermo Fisher Scientific is an American company incorporated in 1956 and is based in Waltham, Massachusetts. The company offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and services worldwide. Moreover, the global team has more than 90,000 colleagues who deliver an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.
VersaTREK Automated Microbial Detection System: The VersaTrek 528 is an automated BC microbial detection system produced by ThermoScientific. It detects pressure changes due to gas consumption (O2) and production (CO2, N2, H2, etc.) by microorganisms in a BC bottle. It is a more advanced and automated instrument than the single detection of CO2 production routinely used in several BC systems. It can detect bacterial pathogens that consume O2 without CO2 production. So it can provide a more credible and reliable result, improve recovery and reduce the TTDs of significant pathogens.
Recent Developments
In March 2026, bioMérieux expanded its automated microbiology systems with advanced AI-driven diagnostic capabilities. The innovation enhances pathogen detection speed and accuracy. This supports improved clinical decision-making and laboratory efficiency.
In February 2026, BD (Becton, Dickinson and Company) introduced next-generation automated microbiology platforms. The systems focus on streamlined workflows and reduced manual intervention. This helps laboratories improve productivity and turnaround times.
In January 2026, Thermo Fisher Scientific enhanced its microbiology automation solutions with integrated data management systems. The platform enables seamless data analysis and reporting. This improves laboratory operations and compliance.
